Logo image of LSDI

LUCY SCIENTIFIC DISCOVERY IN (LSDI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LSDI - CA54960E2033 - Common Stock

0.5139 USD
-0.16 (-23.29%)
Last: 6/28/2024, 8:12:35 PM
0.4552 USD
-0.06 (-11.42%)
After Hours: 6/28/2024, 8:12:35 PM
Fundamental Rating

2

Overall LSDI gets a fundamental rating of 2 out of 10. We evaluated LSDI against 191 industry peers in the Pharmaceuticals industry. LSDI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LSDI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LSDI had negative earnings in the past year.
LSDI had a negative operating cash flow in the past year.
LSDI Yearly Net Income VS EBIT VS OCF VS FCFLSDI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

LSDI has a Return On Assets of -263.59%. This is amonst the worse of the industry: LSDI underperforms 93.26% of its industry peers.
With a Return On Equity value of -13916.75%, LSDI is not doing good in the industry: 87.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -263.59%
ROE -13916.75%
ROIC N/A
ROA(3y)-104.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSDI Yearly ROA, ROE, ROICLSDI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

1.3 Margins

LSDI has a Gross Margin (14.97%) which is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for LSDI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSDI Yearly Profit, Operating, Gross MarginsLSDI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

More info and screens

4

2. Health

2.1 Basic Checks

LSDI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LSDI has been increased compared to 1 year ago.
Compared to 1 year ago, LSDI has an improved debt to assets ratio.
LSDI Yearly Shares OutstandingLSDI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 500K 1M 1.5M
LSDI Yearly Total Debt VS Total AssetsLSDI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -21.67, we must say that LSDI is in the distress zone and has some risk of bankruptcy.
LSDI has a worse Altman-Z score (-21.67) than 86.01% of its industry peers.
There is no outstanding debt for LSDI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.67
ROIC/WACCN/A
WACC7.34%
LSDI Yearly LT Debt VS Equity VS FCFLSDI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 0.38 indicates that LSDI may have some problems paying its short term obligations.
LSDI's Current ratio of 0.38 is on the low side compared to the rest of the industry. LSDI is outperformed by 95.85% of its industry peers.
A Quick Ratio of 0.38 indicates that LSDI may have some problems paying its short term obligations.
LSDI has a Quick ratio of 0.38. This is amonst the worse of the industry: LSDI underperforms 94.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.38
LSDI Yearly Current Assets VS Current LiabilitesLSDI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for LSDI have decreased strongly by -96.67% in the last year.
EPS 1Y (TTM)-96.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.49% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.1%
EPS Next 2Y34.54%
EPS Next 3Y23.49%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSDI Yearly Revenue VS EstimatesLSDI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 10M 20M 30M 40M
LSDI Yearly EPS VS EstimatesLSDI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSDI. In the last year negative earnings were reported.
Also next year LSDI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSDI Price Earnings VS Forward Price EarningsLSDI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSDI Per share dataLSDI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

LSDI's earnings are expected to grow with 23.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.54%
EPS Next 3Y23.49%

More info and screens

0

5. Dividend

5.1 Amount

LSDI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUCY SCIENTIFIC DISCOVERY IN

NASDAQ:LSDI (6/28/2024, 8:12:35 PM)

After market: 0.4552 -0.06 (-11.42%)

0.5139

-0.16 (-23.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13 2024-02-13/amc
Earnings (Next)N/A N/A
Inst Owners7.28%
Inst Owner Change0%
Ins Owners65.53%
Ins Owner Change0%
Market Cap904.46K
Revenue(TTM)16.70K
Net Income(TTM)-11.30M
Analysts82.86
Price Target35.7 (6846.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-211.71%
Min EPS beat(2)-357.52%
Max EPS beat(2)-65.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.27%
Min Revenue beat(2)-100%
Max Revenue beat(2)-96.54%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.16
P/FCF N/A
P/OCF N/A
P/B 11.14
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.2
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-3.61
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0.01
BVpS0.05
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -263.59%
ROE -13916.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.97%
FCFM N/A
ROA(3y)-104.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.38
Altman-Z -21.67
F-Score5
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-96.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.29%
EPS Next Y78.1%
EPS Next 2Y34.54%
EPS Next 3Y23.49%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y23.21%
EBIT Next 5YN/A
FCF growth 1Y-136.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.44%
OCF growth 3YN/A
OCF growth 5YN/A

LUCY SCIENTIFIC DISCOVERY IN / LSDI FAQ

Can you provide the ChartMill fundamental rating for LUCY SCIENTIFIC DISCOVERY IN?

ChartMill assigns a fundamental rating of 2 / 10 to LSDI.


Can you provide the valuation status for LUCY SCIENTIFIC DISCOVERY IN?

ChartMill assigns a valuation rating of 1 / 10 to LUCY SCIENTIFIC DISCOVERY IN (LSDI). This can be considered as Overvalued.


What is the profitability of LSDI stock?

LUCY SCIENTIFIC DISCOVERY IN (LSDI) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for LSDI stock?

The Earnings per Share (EPS) of LUCY SCIENTIFIC DISCOVERY IN (LSDI) is expected to grow by 78.1% in the next year.